Glaxo details cost of drug halt

Drugs giant GlaxoSmithKline revealed today that a dispute over its best-selling anti-depressant had cut its sales growth in the United States by more than half.

Glaxo said pharmaceuticals sales in the US would have grown by 7% between April and June rather than 3% had federal authorities not forced it to halt supplies of Paxil CR in March.